Member of the European Molecular Biology Organization (EMBO)
The scientist’s investigation covers issues in Cystic fibrosis transmembrane conductance regulator, Cystic fibrosis, Cell biology, Mutation and Endoplasmic reticulum. Her Cystic fibrosis transmembrane conductance regulator research is multidisciplinary, incorporating perspectives in Molecular biology, Clinical trial, Surrogate endpoint and Transmembrane protein. Her Cystic fibrosis research entails a greater understanding of Internal medicine.
Her Cell biology study incorporates themes from Proteome, Biochemistry, Caenorhabditis elegans and Genetic screen. Her work deals with themes such as Apical membrane and Protein folding, which intersect with Endoplasmic reticulum. Margarida D. Amaral has included themes like Disease and Allelic heterogeneity in her Genotype study.
Margarida D. Amaral mainly investigates Cystic fibrosis, Cystic fibrosis transmembrane conductance regulator, Cell biology, Molecular biology and Endoplasmic reticulum. Her Cystic fibrosis study is focused on Internal medicine in general. While the research belongs to areas of Internal medicine, Margarida D. Amaral spends her time largely on the problem of Endocrinology, intersecting her research to questions surrounding Genotype-phenotype distinction.
Her Cystic fibrosis transmembrane conductance regulator research is classified as research in Genetics. Her Cell biology research is multidisciplinary, incorporating elements of Regulator, Biochemistry and Transmembrane protein. Margarida D. Amaral has researched Endoplasmic reticulum in several fields, including Chaperone and Protein folding.
Her primary areas of investigation include Cystic fibrosis, Cell biology, Cystic fibrosis transmembrane conductance regulator, Mutation and Chloride channel. Her Cystic fibrosis study improves the overall literature in Internal medicine. Her work carried out in the field of Cell biology brings together such families of science as Regulator, Transcription factor and Mutant.
Margarida D. Amaral has researched Cystic fibrosis transmembrane conductance regulator in several fields, including Cancer and Respiratory tree. Margarida D. Amaral works mostly in the field of Mutation, limiting it down to topics relating to Messenger RNA and, in certain cases, Western blot and Nonsense-mediated decay. Her Chloride channel research includes themes of Secretion, Signal transduction and Actin cytoskeleton.
Margarida D. Amaral mainly investigates Cell biology, Cystic fibrosis, Cystic fibrosis transmembrane conductance regulator, Mutation and Endoplasmic reticulum. Her Chloride channel study, which is part of a larger body of work in Cell biology, is frequently linked to Calcineurin, bridging the gap between disciplines. Her work carried out in the field of Cystic fibrosis brings together such families of science as Basal and Genotype.
By researching both Cystic fibrosis transmembrane conductance regulator and Context, Margarida D. Amaral produces research that crosses academic boundaries. Her research integrates issues of Messenger RNA and Function in her study of Mutation. The Endoplasmic reticulum study combines topics in areas such as ER retention and Interactome.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene
Patrick R Sosnay;Karen R Siklosi;Fredrick Van Goor;Kyle Kaniecki;Kyle Kaniecki.
Nature Genetics (2013)
Progress in Therapies for Cystic Fibrosis
Kris De Boeck;Margarida D Amaral.
The Lancet Respiratory Medicine (2016)
Transcription-dependent spatial arrangements of CFTR and adjacent genes in human cell nuclei
Daniele Zink;Margarida D. Amaral;Andreas Englmann;Susanne Lang.
Journal of Cell Biology (2004)
Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin.
Carlos M. Farinha;Margarida D. Amaral.
Molecular and Cellular Biology (2005)
Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis.
Anabela S. Ramalho;Sebastian Beck;Michelle Meyer;Deborah Penque.
American Journal of Respiratory Cell and Molecular Biology (2002)
New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls
Scott C. Bell;Kris De Boeck;Margarida D. Amaral.
Pharmacology & Therapeutics (2015)
CFTR and chaperones: processing and degradation.
Margarida D. Amaral.
Journal of Molecular Neuroscience (2004)
The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70.
Carlos M. Farinha;Carlos M. Farinha;Paulo Nogueira;Filipa Mendes;Deborah Penque.
Biochemical Journal (2002)
Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis
Margarida D. Amaral;Karl Kunzelmann.
Trends in Pharmacological Sciences (2007)
“CFTR Modulator Theratyping: Current Status, Gaps and Future Directions”
John Paul Clancy;Calvin U. Cotton;Scott H. Donaldson;George M. Solomon.
Journal of Cystic Fibrosis (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: